Lactoferrin für Recurrent Infections

A Evidenz Mehrere große klinische Studien zeigen übereinstimmend signifikante Vorteile.

Meta-analysis shows lactoferrin supplementation may reduce the odds of respiratory tract infections by 40-45%. A 90-day RCT demonstrated 58% reduction in respiratory infections versus placebo. Neonatal trial showed late-onset sepsis at 5.9% with lactoferrin versus 17.3% control.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dlactoferrin\u0026condition\u003Drecurrent\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Fazit

Key Study Findings

Case Reports n=1

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant.

Dose: None vs.: None Outcome: None Wirkung: None None

Population: Patient with specific granule deficiency

Randomized Controlled Trial n=48 26.0 weeks Double-blind

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, …

Dose: 500 mg vs.: Placebo Outcome: Disease remission Wirkung: None None

Population: None

In Vitro

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus.

Dose: None vs.: Conventional antibiotics Outcome: Killing efficacy against extra- and intracellular S. aureus Wirkung: None None

Population: In vitro S. aureus cultures

Observational Study

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.

Dose: None vs.: Healthy controls Outcome: Antibacterial peptide levels in Crohn's disease Wirkung: Decreased defensin and LL-37 in Crohn's patients None

Population: Crohn's disease patients

In Vitro

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10.

Dose: None vs.: None Outcome: immune function Wirkung: None None

Population: animal model

Other n=14 52.0 weeks

Abnormal nasal glandular secretion in recurrent sinusitis.

Dose: 25 mg vs.: baseline Outcome: oxidative stress markers Wirkung: or 2 None

Population: general population

Key Statistics

Studien

2000

Teilnehmer

↑

Positive

Bewertung

Referenced Papers

Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. Case Report

Pediatric allergy, immunology, … 2022 4 Zitierungen

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. RCT

Beneficial microbes 2019 82 Zitierungen

Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Other

Antimicrobial agents and … 2013 115 Zitierungen

Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Other

Lancet (London, England) 2002 519 Zitierungen

Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. Other

Cellular immunology 1991 9 Zitierungen

Abnormal nasal glandular secretion in recurrent sinusitis. Other

The Journal of … 1990 50 Zitierungen

Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. Other

Annals of allergy 1985 1 Zitierungen

Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Other

Blood 1982

Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … Other

The American journal … 1980 138 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:: 100-200 mg/day
immunesupport:: 200-600 mg/day

Obergrenze: No established UL; well-tolerated up to 1,200 mg/day

In der Forschung untersuchte Dosierungen

Dosierung	Dauer	Wirkung	N
None	--	Mixed	1
500 mg	26.0 weeks	Positive	48
None	--	Positive	--
None	--	Negative	--
None	--	Neutral	--
25 mg	52.0 weeks	Mixed	14
None	--	Positive	60
None	468.0 weeks	Mixed	--

Beste Einnahmezeit: On empty stomach

Safety & Side Effects

Gemeldete Nebenwirkungen

⚠ Generally very well tolerated
⚠ Mild gastrointestinal effects at high doses
⚠ Allergic reactions in those with cow's milk allergy
⚠ Constipation (rare, due to iron-binding)

Bekannte Wechselwirkungen

● May enhance absorption of certain antibiotics
● May interact with iron supplements (iron-binding properties)

Tolerierbare Höchstaufnahmemenge: No established UL; well-tolerated up to 1,200 mg/day

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Lactoferrin help with Recurrent Infections?

Based on 8 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Lactoferrin may support Recurrent Infections management. Our evidence grade is A (Strong Evidence).

How much Lactoferrin should I take for Recurrent Infections?

Studies have used various dosages. A commonly studied range is 100-200 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Lactoferrin?

Reported side effects may include Generally very well tolerated, Mild gastrointestinal effects at high doses, Allergic reactions in those with cow's milk allergy, Constipation (rare, due to iron-binding). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Lactoferrin and Recurrent Infections?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Andere Inhaltsstoffe für Recurrent Infections

Bovine Colostrum B

Kurzfazit

Evidence Strength92%

High confidence

Studienübersicht

RCT (1)Meta (0)Other (7)

Alternativen vergleichen

Sehen Sie, wie andere Inhaltsstoffe bei dieser Beschwerde abschneiden.

Alle Inhaltsstoffe ansehen für Recurrent Infections

Mehr erfahren

References

[1] Zeynep Kihtir et al.. Pediatr Allergy Immunol Pulmonol. 2022. Specific Granule Deficiency Due To Novel Homozygote SMARCD2 Variant. doi:10.1089/ped.2021.0070 PubMed
[2] R Russo et al.. Benef Microbes. 2019. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. doi:10.3920/BM2018.0075 PubMed
[3] Jabeen Noore et al.. Antimicrob Agents Chemother. 2013. Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. doi:10.1128/AAC.01650-12 PubMed
[4] Katrin Pütsep et al.. Lancet. 2002. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. doi:10.1016/S0140-6736(02)11201-3 PubMed
[5] C C Brown et al.. Cell Immunol. 1991. Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. doi:10.1016/0008-8749(91)90010-9 PubMed
[6] E V Jeney et al.. J Allergy Clin Immunol. 1990. Abnormal nasal glandular secretion in recurrent sinusitis. doi:10.1016/s0091-6749(05)80117-4 PubMed
[7] J Pryjma et al.. Ann Allergy. 1985. Studies of bronchial secretion. The influence of inflammatory response and bacterial infection. PubMed
[8] J I Gallin et al.. Blood. 1982. Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. PubMed
[9] J Breton-Gorius et al.. Am J Pathol. 1980. Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection … PubMed

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.